Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company advancing targeted therapies for challenging cancers. This page provides investors and researchers with direct access to official announcements and verified updates about the company’s oncology programs.
Key resources include: Clinical trial progress for lead candidate DKN-01 (targeting DKK1), developments in FL-301 (Claudin18.2 program), partnership announcements, and financial disclosures. All content is sourced from authorized releases to ensure reliability.
Users benefit from: Timely updates on regulatory milestones, research collaborations, and pipeline advancements in gastrointestinal/gastroesophageal cancers. Content is organized chronologically for efficient tracking of material events.
Bookmark this page to monitor Leap Therapeutics’ progress in developing precision antibody therapies, with new updates added as official announcements become available.
Leap Therapeutics (NASDAQ:LPTX) announced preclinical data presentation for FL-501, their novel GDF-15 neutralizing antibody, at the AACR 2025 Annual Meeting in Chicago. FL-501 shows promise in treating cancer cachexia, a life-threatening condition characterized by weight loss and muscle wasting.
Key findings demonstrate that FL-501 exhibited a 2-3-fold longer half-life and 50% reduced clearance compared to its wild-type precursor and ponsegromab in humanized FcRn mouse studies. The antibody successfully restored body composition in mouse cachexia models and effectively countered cisplatin-induced weight loss in non-small cell lung cancer patient-derived xenograft models.
The company plans to advance FL-501 into clinical trials in 2026, positioning it as a potential best-in-class treatment option for cancer cachexia, a condition currently lacking effective treatments.
Leap Therapeutics (LPTX) has announced a virtual Key Opinion Leader (KOL) event scheduled for April 23, 2025, at 2:30 p.m. ET to discuss their lead drug candidate sirexatamab (DKN-01) in treating second-line patients with advanced microsatellite stable colorectal cancer.
The event will feature Dr. Zev A. Wainberg, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, who will join Leap's Chief Medical Officer, Dr. Cynthia Sirard, to discuss the unmet needs in colorectal cancer treatment. They will review positive data from Part B of the Phase 2 DeFianCe study of sirexatamab, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.
The presentation will be followed by a live Q&A session, with a replay available on the company's investor relations website.
Leap Therapeutics (LPTX) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical trials. The company's Phase 2 DeFianCe study of sirexatamab showed promising results in colorectal cancer treatment, with a 32% higher overall response rate and 3.5-month longer progression-free survival in patients with high DKK1 levels.
Financial results show a net loss of $67.6 million for 2024, improved from $81.4 million in 2023. Research and development expenses decreased to $57.2 million from $73.2 million, while general and administrative expenses reduced to $12.8 million from $13.8 million. The company maintains $47.2 million in cash as of December 31, 2024.
The company sees a significant market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap has engaged a financial advisor to explore business development opportunities for sirexatamab.
Leap Therapeutics (LPTX) has reported updated data from Part B of the DeFianCe study, evaluating sirexatamab in combination with bevacizumab and chemotherapy for colorectal cancer (CRC) treatment. The study showed significant improvements in multiple patient groups:
In patients with high DKK1 levels, the treatment demonstrated a 32% higher overall response rate (ORR) and 3.5-month longer progression-free survival (PFS). For patients without prior anti-VEGF therapy, results showed a 22% higher ORR and 2.6-month longer PFS.
The treatment combination was well-tolerated, and 34 patients remain on the sirexatamab experimental arm compared to 24 in the control arm. The company sees a substantial market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap plans to proceed with a registrational Phase 3 trial and has engaged financial advisors to explore business development opportunities.
Leap Therapeutics (LPTX) has reported initial data from two clinical studies. In the DeFianCe study Part B, sirexatamab combination therapy showed a 35% objective response rate in second-line colorectal cancer patients, compared to 23% in the control arm. The drug demonstrated particularly strong results in patients with high DKK1 levels, achieving a 48% response rate in the upper quartile.
Key subgroups showed promising results: 51% response rate in anti-VEGF therapy-naive patients, 54% response rate in prior anti-EGFR therapy patients, and 43% response rate in RAS wildtype tumors. The company plans to proceed with Phase 3 registrational studies in second-line colorectal cancer.
However, in the DisTinGuish Part C study for gastric cancer, despite showing activity in biomarker populations, the results did not generate sufficient signals to advance to Phase 3 trials in gastric cancer.
Leap Therapeutics (LPTX), a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Douglas E. Onsi, the company's President and CEO, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 2:15 p.m. Pacific Time.
The presentation will be accessible through a live webcast on the Investors page of Leap Therapeutics' website. A replay of the presentation will be available for a time at https://investors.leaptx.com/.
Leap Therapeutics (Nasdaq: LPTX), a biotech company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Douglas E. Onsi, President and CEO, will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 4:00 p.m. Eastern Time. The presentation will be accessible via live webcast on the company's investor relations website, with a replay available for time viewing.
Leap Therapeutics (LPTX) reported Q3 2024 financial results with a net loss of $18.2 million, compared to $13.7 million in Q3 2023. Research and development expenses increased to $14.9 million from $11.5 million year-over-year. The company completed enrollment in Part B of the Phase 2 DeFianCe study for DKN-01 in colorectal cancer with 188 patients, with data expected mid-2025. Patient follow-up continues in Part C of the DisTinGuish study with 170 patients, with data expected late 2024 or early 2025. Cash position stands at $62.8 million, expected to fund operations into Q2 2026.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
